Candel Therapeutics Inc (NASDAQ:CADL) announced that it will present insights from its enLIGHTEN Discovery Platform, and additional data from the CAN-2409 program, through two accepted poster presentations at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting, from November 5 to 9, 2025 in Maryland.
Paul Peter Tak will also present Candel’s positive phase 3 clinical trial data of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer, including both opportunities and obstacles for developing the next wave of breakthrough therapeutics.